Immunic Therapeutics says it's "on track" in its MS clinical trials of vidofludimus calcium, with CALLIPER top-line data ...

Columnist Ben Hofmeister explains a handy acronym that's helped him and can help you motivate yourself with MS.

Men with MS who started on high-efficacy DMTs had fewer relapses than those who started with moderate-efficacy DMTs, a U.S.

MS patients show large differences between vascular age and chronological age, even if they don't have cardiovascular disease ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

Columnist Ahna Crum is taking on a new year with a different approach: meeting the day-to-day new beginnings in life with ...

Scientists say IRX4204 given to mice with evident symptoms showed potential "as a remyelinating and neurorestorative ...

Long-term Tecfidera use was found to significantly reduce relapse rates and slow disability progression for MS patients in a ...

Certain health issues seen in youth with MS in the five years before diagnosis confirm a prodromal period may exist in ...

Most MS treatments don't increase the risk for miscarriage or major birth defects when used during pregnancy, an analysis ...

The most-read stories published by Multiple Sclerosis News Today in 2024 focused on living with MS and news on disease risk factors.